OA
OABIW
OmniAb, Inc.
$0.0900
0.00%
$14.5M
No data for this timeframe.
Vol
Market Cap$14.5M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$3.4K
SEC Reports4
Exchange Nasdaq·Sector Services-Commercial Physical & Biological Research·Inc. DE·CIK 0001846253·Prev Close $0.0900
Recent Activity
Apr 8, 2026
SEC
Kurt A. Gustafson, an officer of OmniAb, filed a Form 144 to report a proposed sale of 13,542 shares of common stock. Th
144 — Impact 3/10
Apr 8, 2026
SEC
Matthew W. Foehr, an officer of OmniAb, filed a Form 144 to notify the SEC of a proposed sale of 36,459 shares of common
144 — Impact 3/10
Apr 8, 2026
SEC
Charles S. Berkman, an officer of OmniAb, filed a Form 144 to notify of a proposed sale of 13,542 shares of common stock
144 — Impact 3/10
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $3.4K | — |
1 institutional holders with $3.4K total value (19,738 shares) as of 2025-Q3. Top holders: UBS.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 19,738 | $3.4K | 100.0% | — |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 3 neutral. Avg impact: 3.8/10.
NEUTRAL
144
3/10
Kurt A. Gustafson, an officer of OmniAb, filed a Form 144 to report a proposed sale of 13,542 shares
Apr 8, 2026
NEUTRAL
144
3/10
Matthew W. Foehr, an officer of OmniAb, filed a Form 144 to notify the SEC of a proposed sale of 36,
Apr 8, 2026
NEUTRAL
144
3/10
Charles S. Berkman, an officer of OmniAb, filed a Form 144 to notify of a proposed sale of 13,542 sh
Apr 8, 2026
MIXED
8-K
6/10
OmniAb reported a decline in revenue and net loss for 2025 compared to 2024, driven by lower license
Mar 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 20.4% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 141.9% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 65.0% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 49.7% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.